Advancing the Frontier of Immunotherapy in Diffuse Large B-Cell Lymphoma: A Comprehensive Review of Emerging Targets and Multi-Target Strategies

Haolan Ji

doi:10.6911/WSRJ.202511_11(11).0010

Authors

Haolan Ji

DOI:

https://doi.org/10.6911/WSRJ.202511_11(11).0010

Keywords:

Diffuse large B-cell lymphoma (DLBCL), Immunotherapy, CAR-T cell therapy, Bispecific antibodies, Antibody-drug conjugates (ADCs), CD37, ROR1, CD79b, CD70-CD27 axis, BAFF-BAFFR axis, Multi-target therapy, Tumor microenvironment

Abstract

Despite advances with R-CHOP and CD19 CAR-T, many patients develop resistance through antigen escape and immunosuppression. Promising novel targets include CD37, ROR1, CD79b, CD70-CD27, and BAFF-BAFFR axes. Bispecific antibodies, antibody-drug conjugates, and multi-target CAR-T therapies demonstrate enhanced efficacy by overcoming tumor heterogeneity. Future DLBCL management will likely integrate these multi-target approaches with conventional therapies, tailored to molecular profiles for improved outcomes in refractory disease.

Downloads

Download data is not yet available.

References

[1] Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36: 1720-1748.

[2] Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nature Genetics. 2024; 56: 1878-1889.

[3] Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2021; 39: 1317-1328.

[4] Garcia Borrega J, Gödel P, Rüger MA, Onur Ö A, Shimabukuro-Vornhagen A, Kochanek M, et al. In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy. Hemasphere. 2019; 3: e191.

[5] Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research. 2021; 40: 184.

[6] Lapalombella R, Yeh Y-Y, Wang L, Ramanunni A, Rafiq S, Jha S, et al. Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Cancer Cell. 2012; 21: 694-708.

[7] Bobrowicz M, Kubacz M, Slusarczyk A, Winiarska M. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies. Int J Mol Sci. 2020; 21.

[8] Hashwah H, Bertram K, Stirm K, Stelling A, Wu CT, Kasser S, et al. The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma. EMBO Mol Med. 2019; 11: e10576.

[9] Bertoni F, Stathis A. Staining the target: CD37 expression in lymphomas. Blood. 2016; 128: 3022-3023.

[10] Ghaderi A, Daneshmanesh AH, Moshfegh A, Kokhaei P, Vågberg J, Schultz J, et al. ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. Biomedicines. 2020; 8.

[11] Menck K, Heinrichs S, Baden C, Bleckmann A. The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention. Cells. 2021; 10.

[12] Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, et al. Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression. J Immunol. 2022; 209: 2042-2053.

[13] Kwak K, Akkaya M, Pierce SK. B cell signaling in context. Nature Immunology. 2019; 20: 963-969.

[14] Eken JA, Koning MT, Kupcova K, Sepúlveda Yáñez JH, de Groen RAL, Quinten E, et al. Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. J Exp Med. 2024; 221.

[15] Visco C, Tanasi I, Quaglia FM, Ferrarini I, Fraenza C, Krampera M. Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice. Cancers (Basel). 2020; 12.

[16] Sawalha Y, Maddocks K. Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data. Onco Targets Ther. 2020; 13: 5123-5133.

[17] Esquinas E, Moreno-Sanz A, Sandá V, Stodulski-Ciesla D, Borregón J, Peña-Blanque V, et al. Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen. J Immunother Cancer. 2024; 12.

[18] Tkachenko A, Kupcova K, Havranek O. B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells. Int J Mol Sci. 2023; 25.

[19] Xu W, Berning P, Lenz G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood. 2021; 138: 1110-1119.

[20] Siegmund D, Wagner J, Wajant H. TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer. Cancers (Basel). 2022; 14.

[21] Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Current Opinion in Immunology. 2005; 17: 275-281.

[22] Takeda K, Oshima H, Hayakawa Y, Akiba H, Atsuta M, Kobata T, et al. CD27-Mediated Activation of Murine NK Cells1. The Journal of Immunology. 2000; 164: 1741-1745.

[23] Kong F, Ye Q, Xiong Y. Comprehensive analysis of prognosis and immune function of CD70-CD27 signaling axis in pan-cancer. Functional & Integrative Genomics. 2023; 23: 48.

[24] Kumar S, Mahendiran S, Nair RS, Vyas H, Singh SK, Srivastava P, et al. A mechanistic, functional, and clinical perspective on targeting CD70 in cancer. Cancer Letters. 2025; 611: 217428.

[25] Nie M, Ren W, Ye X, Berglund M, Wang X, Fjordén K, et al. The dual role of CD70 in B-cell lymphomagenesis. Clin Transl Med. 2022; 12: e1118.

[26] Liu K, Yang Q, Liu P, Zhu K, Zou M, Zhu Q, et al. CD70 is a potential prognostic marker and significantly regulates cellular function in diffuse large B-cell lymphoma. PLOS ONE. 2024; 19: e0312445.

[27] Sam I, Ben Hamouda N, Alkatrib M, Gonnin C, Siska PJ, Oudard S, et al. The CD70-CD27 Axis in Cancer Immunotherapy: Predictive Biomarker and Therapeutic Target. Clin Cancer Res. 2025; 31: 2872-2881.

[28] Ansell SM, Flinn I, Taylor MH, Sikic BI, Brody J, Nemunaitis J, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Adv. 2020; 4: 1917-1926.

[29] Villasboas JC, Kline JP, Lazaryan A, Bartlett NL, Hernandez-Ilizaliturri FJ, Awan FT, et al. Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL). Journal of Clinical Oncology. 2022; 40: LBA7564-LBA7564.

[30] Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, et al. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro Oncol. 2024; 26: 335-347.

[31] Hu J, Li J, Yang B, Wang S, Bao Y, Yang Y, et al. CD70: An emerging target for integrated cancer diagnosis and therapy. Clinical and Translational Medicine. 2025; 15: e70400.

[32] Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020; 4: e000629.

[33] Vossen MTM, Matmati M, Hertoghs KML, Baars PA, Gent M-R, Leclercq G, et al. CD27 Defines Phenotypically and Functionally Different Human NK Cell Subsets. The Journal of Immunology. 2008; 180: 3739-3745.

[34] Schweighoffer E, Tybulewicz VLJ. BAFF signaling in health and disease. Current Opinion in Immunology. 2021; 71: 124-131.

[35] McAllister E, Jellusova J. BAFF signaling in B cell metabolism. Current Opinion in Immunology. 2021; 71: 69-74.

[36] Ullah MA, Mackay F. The BAFF-APRIL System in Cancer. Cancers (Basel). 2023; 15.

[37] Giordano D, Kuley R, Draves KE, Elkon KB, Giltiay NV, Clark EA. B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease. Front Immunol. 2023; 14: 1050528.

[38] Schweighoffer E, Tybulewicz VL. BAFF signaling in health and disease. Curr Opin Immunol. 2021; 71: 124-131.

[39] Lim K-H, Chen L-C, Hsu K, Chang C-C, Chang C-Y, Kao C-W, et al. BAFF-driven NLRP3 inflammasome activation in B cells. Cell Death & Disease. 2020; 11: 820.

[40] Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barc). 2022; 58: 23-32.

[41] Shin W, Lee HT, Lim H, Lee SH, Son JY, Lee JU, et al. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. Nature Communications. 2018; 9: 1200.

[42] Zhang X, Yang Y, Fan D, Xiong D. The development of bispecific antibodies and their applications in tumor immune escape. Exp Hematol Oncol. 2017; 6: 12.

[43] Liu X, Zhao J, Guo X, Song Y. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting. J Hematol Oncol. 2023; 16: 90.

[44] Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022; 9: e327-e339.

[45] Lu H, Oka A, Coulson M, Polli JR, Aardalen K, Ramones M, et al. PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies. Blood. 2022; 140: 3148-3148.

[46] Bayly-McCredie E, Treisman M, Fiorenza S. Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data. Int J Mol Sci. 2024; 25.

[47] Pan J, Tang K, Luo Y, Seery S, Tan Y, Deng B, et al. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. The Lancet Oncology. 2023; 24: 1229-1241.